Vol. 1 No. 9 (2021)
Reimbursement Recommendations

IncobotulinumtoxinA (Xeomin)

Published September 27, 2021

Key Messages

  • CADTH recommends that Xeomin should be reimbursed by public drug plans for the treatment of chronic sialorrhea associated with neurological disorders if certain conditions are met.
  • Xeomin should only be covered to treat adult patients with moderate to severe chronic troublesome sialorrhea who do not have swallowing difficulties.
  • Xeomin should only be reimbursed if prescribed by a specialist with experience in managing neurological conditions, and the cost of Xeomin is reduced.